Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0968 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 12.5266 |
| Open | 12.5666 |
| 1-Year Change | -16.16% |
| Day's Range | 11.5066 - 12.6966 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 11.5066 | -0.9700 | -7.77% | 12.4766 | 12.6966 | 11.5066 |
| Feb 20, 2025 | 12.5266 | 0.4100 | 3.38% | 12.1166 | 12.5866 | 12.1166 |
| Feb 19, 2025 | 12.0666 | -0.4100 | -3.29% | 12.4766 | 12.6666 | 12.0466 |
| Feb 18, 2025 | 12.6066 | 0.5200 | 4.30% | 12.0866 | 12.7566 | 12.0866 |
| Feb 14, 2025 | 11.9466 | 0.3000 | 2.58% | 11.6466 | 12.0666 | 11.6166 |
| Feb 13, 2025 | 11.7166 | 0.0500 | 0.43% | 11.6666 | 11.8966 | 11.5566 |
| Feb 12, 2025 | 11.5766 | 0.2600 | 2.30% | 11.3166 | 11.5966 | 11.1966 |
| Feb 11, 2025 | 11.4866 | -0.1000 | -0.86% | 11.5866 | 11.6966 | 11.4066 |
| Feb 10, 2025 | 11.8566 | -0.3100 | -2.55% | 12.1666 | 12.1666 | 11.6566 |
| Feb 7, 2025 | 12.0566 | -0.4100 | -3.29% | 12.4666 | 12.4866 | 11.9866 |
| Feb 6, 2025 | 12.6966 | -0.0700 | -0.55% | 12.7666 | 13.0166 | 12.5566 |
| Feb 5, 2025 | 12.7766 | 0.9300 | 7.85% | 11.8466 | 12.8066 | 11.7866 |
| Feb 4, 2025 | 11.8366 | 0.3700 | 3.23% | 11.4666 | 11.8366 | 11.3166 |
| Feb 3, 2025 | 11.5166 | 0.2500 | 2.22% | 11.2666 | 11.5466 | 11.0966 |
| Jan 31, 2025 | 11.4266 | 0.0600 | 0.53% | 11.3666 | 11.6366 | 11.3166 |
| Jan 30, 2025 | 11.4466 | -0.0200 | -0.17% | 11.4666 | 11.7266 | 11.1166 |
| Jan 29, 2025 | 11.4366 | -0.1700 | -1.46% | 11.6066 | 11.6666 | 11.2466 |
| Jan 28, 2025 | 11.6766 | 0.3800 | 3.36% | 11.2966 | 11.7066 | 11.1266 |
| Jan 27, 2025 | 11.3166 | 0.3500 | 3.19% | 10.9666 | 11.6166 | 10.9666 |
| Jan 24, 2025 | 11.1366 | 0.5700 | 5.39% | 10.5666 | 11.1766 | 10.4666 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com